- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01376284
Drug Use Investigation for AVOLVE(BPH)
July 24, 2014 updated by: GlaxoSmithKline
The study is designed to investigate the safety and efficacy of dutasteride capsules 0.5 mg collected from the required number of Japanese subjects with benign prostatic hyperplasia (BPH) in order to identify concerns or problems, if any, about the efficacy and safety of its use at post-marketing clinical settings.
Study Overview
Study Type
Observational
Enrollment (Actual)
1000
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
15 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Sampling Method
Probability Sample
Study Population
Japanese male adult subjects with benign prostatic hyperplasia (BPH) who start the treatment with dutasteride capsules
Description
Inclusion Criteria:
- Must be male subjects
- Use dutasteride capsules for the first time
Exclusion Criteria:
- Subjects who is hypersensitivity to dutasteride or 5α reductase inhibitor
- Subjects with severe hepatic function disorder
- Dutasteride capsules shall not be used to female or child
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Subjects prescribed dutasteride capsules
Subjects with BPH prescribed dutasteride capsules during study period
|
Collection of safety data
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of adverse events in Japanese subjects with BPH treated with dutasteride capsules
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (Actual)
October 1, 2013
Study Completion (Actual)
June 1, 2014
Study Registration Dates
First Submitted
June 9, 2011
First Submitted That Met QC Criteria
June 16, 2011
First Posted (Estimate)
June 20, 2011
Study Record Updates
Last Update Posted (Estimate)
July 28, 2014
Last Update Submitted That Met QC Criteria
July 24, 2014
Last Verified
July 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Prostatic Diseases
- Prostatic Hyperplasia
- Hyperplasia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- 5-alpha Reductase Inhibitors
- Dutasteride
Other Study ID Numbers
- 114125
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Hyperplasia
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
Assiut UniversityNot yet recruiting
-
NeoTract, Inc.Not yet recruitingBenign Prostatic Hyperplasia
-
Assiut UniversityNot yet recruitingBenign Prostatic Hyperplasia
-
Second Affiliated Hospital, School of Medicine,...RecruitingBenign Prostatic HyperplasiaChina
-
Jewish General HospitalNot yet recruitingBenign Prostatic Hyperplasia
-
Zenflow, Inc.RecruitingBenign Prostatic HyperplasiaAustralia, New Zealand
-
REMD Medical TechnologyRenJi Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Sun Yat-Sen... and other collaboratorsCompletedBenign Prostatic HyperplasiaChina
-
Bioaraba Health Research InstituteCompletedBenign Prostatic HyperplasiaSpain
Clinical Trials on Dutasteride
-
GlaxoSmithKlineCompletedAndrogenetic AlopeciaJapan, Argentina, Peru, Philippines, Taiwan, Mexico, Chile, Russian Federation, Thailand
-
Bio-innova Co., LtdNot yet recruiting
-
GlaxoSmithKlineCompletedProstatic Hyperplasia | Benign Prostatic HyperplasiaChina
-
GlaxoSmithKlineCompletedProstatic HyperplasiaUnited States
-
Seoul National University HospitalGlaxoSmithKline; The Korean Urological AssociationCompletedBenign Prostatic Hyperplasia
-
GlaxoSmithKlineCompletedProstatic HyperplasiaJapan
-
Northwestern UniversityGlaxoSmithKlineTerminatedBenign Prostatic Hyperplasia
-
University of California, San FranciscoCompletedProstate Cancer | Nonmalignant NeoplasmUnited States
-
GlaxoSmithKlineCompletedNeoplasms, ProstateFrance, Germany, Spain, United States, Netherlands, Canada, United Kingdom, Finland, Chile, Sweden, Argentina, Greece
-
Urology of VirginiaGlaxoSmithKlineUnknownLower Urinary Tract Symptoms | Benign Prostatic HyperplasiaUnited States